Lapa Constantin
Department of Nuclear Medicine, University Hospital Augsburg, Stenglinstr. 2, 86156 Augsburg, Germany.
J Clin Med. 2019 Nov 12;8(11):1944. doi: 10.3390/jcm8111944.
Nuclear medicine has experienced a number of unprecedented developments in recent years. Above all, the concept of "theranostics", the combination of a predictive biomarker with a therapeutic agent, has been a central part of this success. For example, a phase III randomized, controlled trial provided unequivocal evidence of the effectiveness of 177Lu-DOTATATE for treatment of neuroendocrine tumors, and there have been multiple reports of the benefits of prostate-specific membrane antigen targeted PET imaging and radio-ligand therapy in prostate cancer. Other new exciting theranostic applications include, among many others, C-X-C motif chemokine receptor 4, as well as cancer-associated fibroblasts. These can be specifically addressed by inhibitors of the fibroblast activation protein and represent a particularly promising target for nuclear medicine theranostics. This Special Issue presents some of the most recent advances in the field of nuclear medicine.
近年来，核医学经历了一些前所未有的发展。最重要的是，“治疗诊断学”的概念，即将预测性生物标志物与治疗剂相结合，一直是这一成功的核心部分。例如，一项III期随机对照试验明确证明了177Lu-DOTATATE治疗神经内分泌肿瘤的有效性，并且有多项报告表明前列腺特异性膜抗原靶向PET成像和放射性配体疗法在前列腺癌中的益处。其他令人兴奋的新型治疗诊断应用包括许多其他方面，如C-X-C基序趋化因子受体4以及癌症相关成纤维细胞。成纤维细胞活化蛋白抑制剂可以特异性地作用于这些靶点，是核医学治疗诊断学特别有前景的靶点。本期特刊展示了核医学领域的一些最新进展。
